Document is current
Any future updates will be listed below
-
Authors
Nguyen, Maxime https://orcid.org/0000-0002-2334-1487
Alvarez, Marvin
Evezard, Corentin
Berthoud, Vivien
Leleu, Damien
Pais-De-Barros, Jean-Paul
Bouchot, Olivier
Abou-Arab, Osama
Bouhemad, Belaid
Masson, David
Gautier, Thomas
Guinot, Pierre-Grégoire
-
Funding
Funding for this research was provided by:
Baxter Healthcare Corporation
- License Information
-
More Information
Article History
Received: 19 March 2025
Accepted: 8 June 2025
First Online: 8 July 2025
Declarations
:
: This research was approved by the institutional review board (CPP Sud-ouest et Outre-mer II, France; ref. 2021-A00097-34). Informed consent was obtained from all patients or their next of kin prior to inclusion.
: MN: consulting honoraria and research grand from BAXTER, MN: formation fee Fresenius, MN: Congress fee Pfizer. PGG receive fees for lecture from Aguettant, AOP, BAXTER, Medtronic, Edwards and Vygon. PGG is consultant for ABBOT. VB received fees for lecture from AOP and LFB. OAA: research grand from BAXTER. Baxter, Oxiris, Prismaflex and PrisMax are trademarks of Baxter International Inc. or its subsidiaries.
